论文部分内容阅读
目的研究信号传导及转录活化子(signaltransducerandactivatoroftranscription3,STAT3)在非小细胞肺癌中的表达,探讨STAT3在非小细胞肺癌中表达的临床特点,以及STAT3对非小细胞肺癌患者预后的影响。方法取辽宁省肿瘤医院胸外科1997年12月￣1998年12月71例有随访的非小细胞肺癌手术标本的石蜡切片,采用免疫组化SABC法进行染色分析,判断STAT3在非小细胞肺癌中的表达率。探讨STAT3的表达与年龄、性别、肿瘤位置、肿瘤分化程度、病理分型、淋巴结转移(N)、原发肿瘤进展(T)及肿瘤分期的关系,应用生存分析研究STAT3对非小细胞肺癌患者预后的影响。结果在全部71例患者中,共有26例患者STAT3表达阳性,阳性表达率为36.62%。STAT3的表达与原发肿瘤进展(T)和肿瘤分期明显正相关(P=0.012,0.0000),T值越高,肿瘤分期越晚,STAT3表达量越多。有淋巴结转移的患者中,原发肿瘤STAT3阳性表达率高(P=0.003),且转移淋巴结的癌组织中STAT3阳性表达率高达86.96%(20/23)(P=0.001)。STAT3表达阳性的患者预后较STAT3表达阴性的患者差(P=0.005)。结论提示STAT3在非小细胞肺癌的侵袭和淋巴结转移机制中可能起一定作用。STAT3阳性表达的非小细胞肺癌患者预后差,STAT3可作为非小细胞肺癌预后的辅助预测因子。
Objective To investigate the expression of signal transducer and activator of transcription 3 (STAT3) in non-small cell lung cancer (NSCLC) and to investigate the clinical features of STAT3 expression in non-small cell lung cancer and the effect of STAT3 on the prognosis of patients with non-small cell lung cancer. Methods A total of 71 paraffin sections from non-small cell lung cancer (NSCLC) specimens were followed up from December 1997 to December 1998 in the Department of Thoracic Surgery, Liaoning Provincial Cancer Hospital. Immunohistochemical SABC staining was performed to determine STAT3 in non-small cell lung cancer. The rate of expression. To investigate the relationship between STAT3 expression and age, sex, tumor location, tumor differentiation, pathological type, lymph node metastasis (N), primary tumor progression (T) and tumor stage. Survival analysis was used to study STAT3 in non-small cell lung cancer patients. The impact of prognosis. RESULTS: Of the 71 patients, STAT3 expression was positive in 26 patients. The positive expression rate was 36.62%. The expression of STAT3 was positively correlated with the progression of primary tumor (T) and tumor stage (P=0.012, 0.0000). The higher the T value, the later the tumor stage and the more STAT3 expression. In patients with lymph node metastasis, the positive rate of STAT3 expression in primary tumors was high (P = 0.003), and the positive rate of STAT3 expression in cancer tissues with metastatic lymph nodes was as high as 86.96% (20/23) (P = 0.001). Patients with positive STAT3 expression had a worse prognosis than those with negative STAT3 expression (P=0.005). Conclusions suggest that STAT3 may play a role in the invasion and lymph node metastasis of non-small cell lung cancer. The prognosis of patients with non-small cell lung cancer positively expressed by STAT3 is poor, and STAT3 can be used as an auxiliary predictor of prognosis of non-small cell lung cancer.